Clinical Trials Directory

Trials / Completed

CompletedNCT04730882

Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults

Status
Completed
Phase
Study type
Observational
Enrollment
36 (actual)
Sponsor
University of Virginia · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

To the investigator's knowledge, there are no data available in the current literature regarding the acute effects of postprandial hyperglycemia and insulin timing on myocardial perfusion in people with type 1 diabetes (T1D). Observational studies using CEU in type 2 diabetes demonstrate that postprandial hyperglycemia determines myocardial perfusion defects. The investigator hypothesizes that the combination of postprandial hyperglycemia and insulin increases pulse wave velocity (i.e., aortic stiffness) and myocardial vasoconstriction, thereby reducing myocardial perfusion in T1D when compared to healthy controls. Furthermore, the investigator hypothesizes in T1D that dosing insulin before meal intake will ameliorate these cardiovascular defects.

Detailed description

The investigator will compare 17 T1D and 17 age-, sex-, and BMI-matched healthy controls (18-35 yrs) measuring pulse wave velocity (PWV), flow-mediated dilation (FMD) and myocardial perfusion (contrast enhanced ultrasound \[CEU\]) before and 2 hours after ingesting a mixed meal (40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively). T1D participants will have 2 study admissions: A) injection of insulin 15 minutes before ingesting a mixed meal. B) injection of insulin 15 min after ingesting a mixed meal.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTMixed Mealthe meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively

Timeline

Start date
2021-04-06
Primary completion
2024-10-18
Completion
2024-10-18
First posted
2021-01-29
Last updated
2025-03-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04730882. Inclusion in this directory is not an endorsement.